MedTrace Logo

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome

NCT02025608 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-01-24

No results posted yet for this study

Summary

The purpose of this study is to explore whether patients with restless legs syndrome (RLS) differ from healthy subjects in daytime and night time autonomic function and cardiovascular risk markers and whether 4 week treatment with pramipexole affects autonomic function and cardiovascular risk markers in patients with RLS.

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

Pramipexole

DRUG

Placebo

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • Cardiocentro Ticino

    collaborator OTHER

  • Mauro Manconi

    lead OTHER

Principal Investigators

  • Mauro Manconi, PhD, MD · Neurocenter of Southern Switzerland

  • Claudio L.A. Bassetti, MD · Department of Neurology, Inselspital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02025608 on ClinicalTrials.gov